Simplify Logo
Pfizer

Pfizer

Biopharmaceutical company develops medicines and vaccines

Senior Machine Learning Artificial Intelligence Cheminformatics Scientist - Pharmacokinetics, Dynamics, and Metabolism

Full-TimeUpdated on 9/21/2026
$93.6k - $156k/yr

+ 12.5% bonus target + Share-based long-term incentive program

Mid, Senior
Master's, PhD
Groton, CT, USA
Hybrid

Hybrid schedule requires living within commuting distance and working on-site an average of 2.5 days per week. Some travel is required; relocation support may be available.

No H1B Sponsorship

About the job

Requirements
  • A PhD in a relevant field or a relevant master's degree with at least 2 years of experience in cheminformatics, computational chemistry, bioinformatics, data science, or a related field.
  • Proficiency in Python and experience with cheminformatics libraries and topics including RDKit, OpenEye, DeepChem, InChI, and SMILES/SMARTS.
  • Experience working in a structured collaborative data and software development environment using Git.
  • Experience using structure-activity relationship model-building software such as scikit-learn and Torch.
  • A strong understanding of basic statistical concepts and methods for evaluating and tracking model performance.
  • Ability to perform mathematical calculations and complex data analysis.
  • Authorization to be employed in the United States by any employer and permanent work authorization in the United States.
Responsibilities
  • Develop and apply cheminformatics data-mining algorithms to analyze molecular modeling, virtual screening, and structure-activity relationship analysis.
  • Process and analyze chemical and biological datasets to evaluate drug-likeness, ADMET properties, dosing, and related molecular properties.
  • Utilize molecular fingerprints, descriptors, and similarity metrics for compound clustering, classification, and regression.
  • Assist in developing, maintaining, and monitoring artificial intelligence and machine learning models for property prediction.
  • Optimize data pipelines for processing and storing chemical structures using cheminformatics toolkits such as RDKit and OpenEye.
  • Collaborate with cross-functional teams to integrate computational approaches into curation and analysis workflows.
  • Maintain best practices in data integrity, reproducibility, and documentation of quantitative structure-activity relationship artificial intelligence and machine learning models.
Desired Qualifications
  • Experience using directed acyclic graphs to define data pipelines, including Luigi, Airflow, Dagster, Prefect, or Kubeflow.
  • Experience working with relational SQL and NoSQL databases for chemical data management.
  • Experience working with machine learning operations tools such as MLflow, Neptune, or SageMaker.

About the company

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 27, 2026 FDA approval relaunched Comirnaty XFG for the fall vaccine season.
  • Pfizer raised 2026 revenue guidance to $60.5 billion-$62.5 billion on stronger non-COVID products.
  • 2026 obesity and oncology catalysts include berobenatide, atirmociclib, and sigvotatug vedotin.

What critics are saying

  • Eliquis patent expiry in 2028 and Ibrance in 2027 crushes 2027-2030 revenue.
  • September 2026 FDA limits Comirnaty XFG to seniors and high-risk patients, shrinking demand.
  • Generic pricing antitrust suits and manufacturing cuts in Ireland expose operational strain.

What makes Pfizer unique

  • Pfizer pairs global scale with BioNTech mRNA manufacturing and distribution reach.
  • Eliquis, Padcev, and Vyndaqel offset aging COVID revenue and fund the transition.
  • Pfizer can run late-stage oncology and obesity programs simultaneously, unlike smaller biotechs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-5%

1 year growth

-5%

2 year growth

-5%
Yahoo Finance
Sep 20th, 2026
Pfizer CEO says major headwinds easing as drugmaker cuts $7.2B in costs, eyes oncology pipeline

Pfizer's chief executive Albert Bourla says the pharmaceutical company's major headwinds are easing. Speaking at a recent conference, Bourla identified three challenges facing the drugmaker in 2025: tariffs and drug pricing policies, declining coronavirus product sales, and patent cliffs. The company has addressed tariffs by signing agreements with the US government for reduced medicine prices in exchange for tariff breaks. Pfizer has exceeded Wall Street's earnings-per-share estimates in all 10 of its past quarterly reports, suggesting its coronavirus business no longer significantly impacts performance. However, major patent cliffs loom. Eliquis, which generated $4.6 billion in the first half of the year, could face generic competition by 2028. Cancer treatment Ibrance, with $2.1 billion in first-half revenue, faces US patent expiration in 2027. Pfizer has cut $7.2 billion in costs and expanded its pipeline through acquisitions and internal development, with new products generating $13 billion annually. The company offers a 6.2% dividend yield.

Yahoo Finance
Sep 10th, 2026
Medicus Pharma secures Pfizer ADC deal with $2M funding, advances SkinJect for rare cancer treatment

Medicus Pharma has secured a development and licensing agreement with Pfizer for a CD228-targeted antibody-drug conjugate programme focused on solid tumours, including refractory melanoma. Pfizer is providing approximately $2 million in development funding, plus inventory and infrastructure support. CEO Dr Raza Bokhari said the deal allows Medicus to continue from where Pfizer concluded its Phase 1 dose-escalation work, strengthening the company's position in precision oncology. Medicus is also advancing its SkinJect programme for basal cell carcinoma. Final clinical trial results identified the 200-microgram patch as the optimal dose for future studies. The company is preparing for the FDA-approved pivotal SkinJect 005 study whilst recruiting patients. An independent reimbursement analysis suggests SkinJect could achieve reimbursement levels of $25,000 or more per patient.

Yahoo Finance
Sep 8th, 2026
AbbVie beats Pfizer as top dividend stock with 53-year payout streak and 203% growth

AbbVie offers a smarter long-term dividend investment than Pfizer, despite Pfizer's higher 6.1% yield. AbbVie holds Dividend King status with 53 consecutive years of dividend increases and raised its payout by 5.5% this year to $1.73 per share. Over the past decade, AbbVie increased its dividend by more than 203% compared to Pfizer's 51%. AbbVie's revenue grew 138% during this period, whilst Pfizer's rose just 18%. AbbVie successfully navigated Humira's patent cliff through home-grown immunology drugs Skyrizi and Rinvoq. By 2025, these two drugs generated combined annual sales exceeding $25 billion, replacing Humira's peak revenue and pushing total company revenue to record highs. AbbVie's free-cash-flow dividend payout ratio stands at 65%, lower than Pfizer's 89%.

Yahoo Finance
Aug 28th, 2026
Pfizer's updated COVID vaccine ships as FDA approves narrower rollout for over-65s and high-risk groups

Pfizer received FDA approval for its updated Comirnaty COVID-19 vaccine on Thursday, with deliveries to pharmacies and clinics beginning immediately. The company's shares were trading at $27.9079 on 28 August. However, the market opportunity has significantly narrowed from pandemic levels. Eligibility is now limited to adults aged 65 and older, plus higher-risk patients aged 5 through 64. Despite Comirnaty having distributed over five billion doses worldwide historically, today's revenue potential is considerably more constrained. Pfizer faces competition from Moderna and the Novavax-Sanofi protein vaccine for this smaller patient pool. The company's current share price sits 5.27% above its estimated value of $26.51, suggesting investors are paying a premium before actual uptake and commercial results become clear.

Associated Press
Aug 27th, 2026
FDA approves Pfizer-BioNTech XFG-adapted COVID-19 vaccine for high-risk groups

Pfizer and BioNTech have received US Food and Drug Administration (FDA) approval for their 2026-2027 COVID-19 vaccine targeting the XFG variant. The vaccine is approved for adults aged 65 and older, and individuals aged 5 to 64 with underlying conditions that increase risk of severe COVID-19 outcomes. The FDA approval is based on clinical, non-clinical and real-world data demonstrating the vaccine generates strong immune responses against currently circulating SARS-CoV-2 variants, including XFG and other contemporary lineages. The XFG variant was selected following FDA guidance for fall 2026 vaccine composition. The vaccine will begin shipping immediately and will be available in US pharmacies, hospitals and clinics within days. To date, more than five billion doses of COMIRNATY have been distributed globally.